© 2026 | Jefferson Public Radio
Southern Oregon University
1250 Siskiyou Blvd.
Ashland, OR 97520
541.552.6301 | 800.782.6191
Listen | Discover | Engage a service of Southern Oregon University
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

OSU research targets skin cancer with nanotechnology and lasers

Oregon State University research has discovered unique nanoparticle properties that can be a less-invasive alternative treatment of melanoma. Early tests in mice have produced results showing complete elimination of cancerous tumors.
Oregon State University Olena Taratula Lab
Oregon State University research has discovered unique nanoparticle properties that can be a less-invasive alternative treatment of melanoma. Early tests in mice have produced results showing complete elimination of cancerous tumors.

Researchers at Oregon State University say they have developed a light-activated treatment that eliminated aggressive melanoma tumors in laboratory mice after a single session.

The technique uses microscopic particles, sometimes called “nanoheaters,” that absorb light and convert it into heat to destroy cancer cells. The particles are activated by a low-intensity laser, similar in strength to a laser pointer.

Olena Taratula, a professor of pharmaceutics at Oregon State University, said the approach targets tumors while minimizing damage to surrounding tissue.

“The heat is only produced when you have the light present in combination with nanoparticles,” Taratula said. “The tissue is basically eradicated.”

In mouse models, researchers reported that tumors disappeared after a 10-minute treatment and did not return during the study period. “Within a week, we already saw the tumor disappearing,” Taratula said.

Researchers said the method could have applications beyond melanoma. Taratula’s lab also studies conditions such as endometriosis and ectopic pregnancy, which involve rapid capillary growth similar to cancer. She said nanoparticles can be designed to accumulate in specific tissues, allowing targeted treatment.

Clinical trials in humans are still several years away. Researchers said the technology represents a potential step toward more precise and less invasive therapies.

Guest

  • Olena Taralua, professor of pharmaceutics at Oregon State University
Stay Connected
Mike Green is host of the Jefferson Exchange. Mike has lived in Southern Oregon for more than two decades. He is an award-winning journalist with over 20 years experience in media, specializing in media innovation, inclusive economics and entrepreneurship.
Natalie Golay is the Senior Producer of the Jefferson Exchange. She has a B.A. in Visual Arts, a certificate of recommendation in multimedia from the Vancouver Film school, and a law degree from the University of British Columbia. A communications professional for over 20 years, Natalie is a natural storyteller with extensive audio and video production skills.